Thermo Fisher Scientific(US:TMO) Zhao Yin Guo Ji·2025-10-24 02:37Macro Commentary - The core objective of China's "14th Five-Year Plan" (2026-2030) emphasizes high-quality development, shifting focus from GDP growth to technological self-reliance and economic transformation [2][4] - Key strategic industries highlighted include artificial intelligence, semiconductors, advanced robotics, green energy, aerospace, and industrial software [2] - The plan aims to rebalance the economy towards consumption-driven growth, with increased investment in social services such as healthcare and elder care, benefiting sectors like consumer staples and healthcare [2][4] Market Performance - The Hang Seng Index closed at 25,968, up 0.72% year-to-date performance is 29.45% [2] - The Shanghai Composite Index closed at 3,922, with a year-to-date increase of 17.03% [2] - U.S. markets showed positive performance, with the Dow Jones up 0.27% and the S&P 500 up 0.49% [2][4] Company Analysis - Giant Bio (2367 HK): The approval of its first injectable aesthetic product marks the beginning of a new growth phase for the company. The product is aimed at facial dermal filling to correct dynamic wrinkles [5][6] - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic market, which is expected to drive growth [5] - Thermo Fisher (TMO US): Reported a strong 3Q25 performance with a revenue increase of 5.0% year-on-year and an adjusted EPS growth of 9.7%. The company raised its full-year guidance based on robust performance [6][7] - The demand from pharma and biotech clients is showing positive signs, with revenue growth driven by bioproduction and analytical instruments [7][8] - The company is expected to benefit from the trend of pharmaceutical companies establishing manufacturing facilities in the U.S., which will reflect in its performance by 2027-2028 [9]